IMMUNEERING CORP - CLASS A (IMRX)

US45254E1073 - Common Stock

2.2  +0.2 (+10%)

Premarket: 2.19 -0.01 (-0.45%)

IMMUNEERING CORP - CLASS A

NASDAQ:IMRX (12/23/2024, 8:12:17 PM)

Premarket: 2.19 -0.01 (-0.45%)

2.2

+0.2 (+10%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%-13.95%
Sales Q2Q%N/A
CRS6.27
6 Month71.88%
Overview
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Ins Owners19.84%
Inst Owners32.46%
Market Cap68.31M
Shares31.05M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts80
Short Float %7.22%
Short Ratio1.44
IPO07-30 2021-07-30
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

IMRX Daily chart

Company Profile

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2021-07-30. The firm is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the MAPK pathway. The Company’s second product candidate, IMM-6-415, aims to achieve universal-MAPK activity with an accelerated twice-daily oral dosing cadence, also through deep cyclic inhibition of the MAPK pathway. IMM-6-415 is in Investigational New Drug application (IND), enabling studies. Its pipeline also includes Trifecta MEK, RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

Company Info

IMMUNEERING CORP - CLASS A

245 Main Street, Second Floor

Cambridge MASSACHUSETTS

P: 16175008080

CEO: Benjamin J. Zeskind

Employees: 66

Website: https://immuneering.com/

IMRX News

News Image18 hours ago - USA News GroupHow Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

/PRNewswire/ -- USA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative...

News Image5 days ago - Immuneering CorporationImmuneering Launches Pancreatic Cancer Advisory Board
News Image5 days ago - Immuneering CorporationImmuneering Launches Pancreatic Cancer Advisory Board

Immuneering Launches Pancreatic Cancer Advisory Board ...

News Image7 days ago - Immuneering CorporationImmuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
News Image7 days ago - Immuneering CorporationImmuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025...

ChartMill News Image12 days ago - ChartmillStay updated with the stocks that are on the move in today's pre-market session.

The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

IMRX Twits

Here you can normally see the latest stock twits on IMRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example